Pharma and AI: Help doctors with AI assistants but don’t try to replace them
16 February 2018
Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors.
Pharma Looks to Change the Healthcare Cost Conversation
15 February 2018
Amidst the continuing clamor for government action to curb prescription drug prices, a more collaborative effort aims to broaden the debate to consider the full range of healthcare services and rates that affect spending in this area. The National Pharmaceutical Council (NPC), a pharma-funded research organization, is partnering with the independent journal Health Affairs to examine the root causes of rising healthcare outlays in the United States. This two-year program will support academic and professional research projects and commentaries to be published and disseminated online by the journal.
FDA Releases Guidance on Systemic Antibacterial Drugs
15 February 2018
FDA published guidance on the development, analysis, and presentation of microbiology data during the development of antibacterial drugs. The agency discusses the overall microbiology development program it says is needed to support clinical development and approval of antibacterial drugs administered systemically. The guidance also addresses microbiology data collected after drug approval.
EMA discussed its future premises in Amsterdam
14 February 2018
The European Medicines Agency’s (EMA) Management Board met in an extraordinary session to discuss EMA’s future premises in Amsterdam. EMA will move from London to Amsterdam before the end of March 2019, when the United Kingdom withdraws from the European Union (EU).
Russian pharmacy market increased by 6.5% in ruble terms in 2017
14 February 2018
In 2017, 5065.8 million packages of drugs worth 940.7 billion rubles (in retail prices) were sold through the pharmacies in Russia. This is 6.5% higher than in 2016 in value terms and 3.5% higher in physical terms. The positive dynamics in terms of packages sold in 2017 indicates the improved purchasing power of consumers and lower impact of financial and economic factors on the pharmacy market.
Expect augmented reality to come up big for pharma marketers: expert
13 February 2018
"Show, don’t tell" could become a new maxim in pharma marketing. That’s because the rise of augmented reality, although still nascent, is emerging as a valuable technique in pharma visuals, according to life sciences cloud-computing company Veeva Systems.
Moscow-based pharmaceutical companies increased their annual output by 40%
13 February 2018
In 2017, the manufacturing of drugs in Moscow increased by 40%, announced the Department of Economic Policy and Development of the city government. “The high-tech sectors of the real economy, including pharmaceutical and IT production companies accounting for 20% of the demand for the office space in Moscow, are the priorities for the new industrial policy of the city. In 2017, the manufacturing of drugs in Moscow increased by 40%,” said the Department.
Roszdravnadzor is authorized to make control purchases of drugs
12 February 2018
At its meeting held on February 7, 2018, the Russian State Duma adopted in the first reading a draft law that authorizes Roszdravnadzor to make control purchases, which will allow to combat the sales of substandard medicines and violations of the rules for providing paid medical services.
Can emerging technology help biopharma improve the returns on R&D?
09 February 2018
Nearly $2 billion. That’s the average cost to bring a new drug to market, according to Deloitte’s latest report on research and development (R&D) costs, and returns, among 12 of the world’s leading biopharmaceutical manufacturers. While our study finds that biopharma companies are investing more than ever to develop innovative and effective therapies, their returns aren’t keeping pace.
New Skoltech supercomputer will improve the effectiveness of drug development
09 February 2018
By the summer, the performance of the supercomputer at the SKOLKOVO Institute of Science and Technology is expected to rise to 1.5 petaflops. Maxim Fedorov, the Director of Skoltech Center for Computational and Data-Intensive Science and Engineering, said that, currently, Skoltech has several hybrid clusters (GPU/CPU) with a total performance of about 100 TF.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024